Peroxisome proliferator–activated receptor γ and the transcriptional control of adipogenesis and metabolism

Handbook of Obesity: Etiology and Pathophysiology, Second Edition

Volumn , Issue , 2003, Pages 559-587

  Fajas, Lluis ^a   Auwerx, Johan ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85017364406     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (276)

1. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H. Organization, promoter analysis and expression of the human PPARg gene. J Biol Chem 1997; 272:18779–18789.
2. Zhu Y, Qi C, Korenberg JR, Chen X-N, Noya D, Rao MS, Reddy JK. Structural organization of mouse peroxisome proliferator activated receptor γ (mPPARg) gene: alternative promoter use and different splicing yield two mPPARg isoforms. Proc Natl Acad Sci USA 1995; 92:7921–7925.
3. Fajas L, Fruchart JC, Auwerx J. PPARg3 mRNA: a distinct PPARg mRNA subtype transcribed from an independent promoter. FEBS Lett 1998; 438:55–60.
4. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal h-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992; 68:879–887.
5. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Laville M, Staels B, Auwerx J, Vidal H. Tissue distribution and quantification of the expression of PPARs and LXRa in humans: no alterations in adipose tissue of obese and NIDDM patients. Diabetes 1997; 48:1319–1327.
6. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998; 95:7614–7619.
7. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS. Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99:2416–2422.
8. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS, Möller DE. Regulation of PPARγ gene expression by nutrition and obesity in rodents. J Clin Invest 1996; 97:2553–2561.
9. Lefebvre AM, Laville M, Vega N, Riou JP, Van Gaal L, Auwerx J, Vidal H. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 1998; 47:98–103.
10. Rieusset J, Andreelli D, Auboeuf D, Roques P, Valier P, Riou JP, Auwerx J, Laville M, Vidal H. Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor γ in human adipocytes. Diabetes 1999; 48:699–705.
11. Xing H, Northrop JP, Grove JR, Kilpatrick KE, Su JL, Ringold GM. TNFa-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARγ without effects on Pref-1 expression. Endocrinology 1997; 138:2776–2783.
12. Hill M, Young M, McCurdy C, Gimble J. Decreased expression of murine PPARγ in adipose tissue during endotoxinemia. Endocrinology 1997; 138:3073–3076.
13. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 37:907–925.
14. Moras D, Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol 1998; 10(3):384–391.
15. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV. Ligand binding and coactivator assembly of the peroxisome proliferator-activated receptor γ. Nature 1998; 395:137–143.
16. Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, Berkenstam A. Crystal structure of the ligand binding domain of the human nuclear receptor PPARγ. J Biol Chem 1998; 273:31108–31112.
17. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA, Milburn MV. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999; 3(3):397–403.
18. Johnson BA, Wilson EM, Li Y, Möller DE, Smith RG, Zhou G. Ligand-induced stabilization of PPAR-gamma monitored by NMR spectroscopy: implications for nuclear receptor activition. J Mol Biol 2000; 298(2):187–194.
19. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-a. Nature 1995; 375:377–382.
20. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 1995; 378(6558):681–689.
21. Le Douarin B, Nielsen AL, Garnier JM, Ichinose H, Jeanmougin F, Losson R, Chambon P. A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. EMBO J 1996; 15(23):6701–6715.
22. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG. The transcriptional coactivator P/CIP binds CBP and mediates nuclear-receptor function [see comments]. Nature 1997; 387(6634):677–684.
23. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional coactivators mediates binding to nuclear receptors. Nature 1997; 387:733–736.
24. Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr CP, Blanchard SG, Parks DJ, Moore LB, Lehmann JM, Plunket K, Miller AB. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 1999; 96(11):6102–6106.
25. Gampe RTJ, Montana VG, Lambert MH, Miller AB, Bledsoe RK, Milburn MV, Kliewer SA, Willson TM, Xu HE. Asymmetry in the PPAR gamma-RXR alpha crystal structure reveals the molecular basis of hetero-dimerization among nuclear receptors. Mol Cell 2000; 5:545–555.
26. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389(6652):753–758.
27. Bourguet W, Vivat V, Wurtz JM, Chambon P, Gronemeyer H, Moras D. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol Cell 2000; 5:289–298.
28. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83:841–850.
29. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87:377–389.
30. Fajas L, Fruchart JC, Auwerx J. Transcriptional control of adipogenesis. Curr Opin Cell Biol 1998; 10:165–173.
31. Ding Q, Wang Q, Dong Z, Evers BM. Characterization and regulation of E2F activity during Caco-2 cell differentiation. Am J Physiol Cell Physiol 2000; 278(1):C110-C117.
32. Rempel RE, Saenz-Robles MT, Storms R, Morham S, Ishida S, Engel A, Jakoi L, Melhem MF, Pipas JM, Smith C, Nevins JR. Loss of E2F4 activity leads to abnormal development of multiple cellular lineages. Mol Cell 2000; 6(2):293–306.
33. Persengiev SP, Kondova, II, Kilpatrick DL. E2F4 actively promotes the initiation and maintenance of nerve growth factor-Induced cell differentiation. Mol Cell Biol 1999; 19(9):6048–6056.
34. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000; 14(19):2393–2409.
35. Helin K. Regulation of cell proliferation by the E2F transcription factors. Curr Opin Genet Dev 1998; 8(1):28–35.
36. Richon V, Lyle RE, McGehee REJ. Regulation and expression of retinoblastoma proteins p107 and p130 during 3T3-L1 adipocyte differentiation. J Biol Chem 1997; 272:10117–10124.
37. Higgins C, Chatterjee S, Cherington V. The block of adipocyte differentiation by a C-terminally truncated, but not by full-length, simian virus 40 large tumor antigen is dependent on an intact retinoblastoma susceptibility protein family binding domain. J Virol 1996; 70(2):745–752.
38. Classon M, Kennedy BK, Mulloy R, Harlow E. Opposing roles of pRB and p107 in adipocyte differentiation [in process citation]. Proc Natl Acad Sci USA 2000; 97(20):10826–10831.
39. Chen PL, Riley DJ, Chen Y, Lee WH. Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev 1996; 10(21):2794–2804.
40. Fajas L, Egler V, Reiter R, Hausen J, Kristiansen K, Debril M-B, Miarol S, Auwerx J. The retinoblastoma-histone deacetylase 3 complex inhibits PPARJ and adipocyte differentiation. Developmental Cell 2002; 3:903–910.
41. He GP, Muise A, Li AW, Ro HS. A eucaryotic transcriptional repressor with carboxypeptidase activity. Nature 1995; 378:92–96.
42. Park J-G, Muise A, He G-P, Kim S-W, Ro H-S. Transcriptional regulation by the γ5 subunit of a heterotrimeric G protein during adipogenesis/. EMBO J 1999; 18:4004–4012.
43. Tong Q, Dalgin G, Xu H, Ting CN, Leiden JM, Hotamisligil GS. Function of GATA transcription factors in preadipocyte-adipocyte transition [in process citation]. Science 2000; 290(5489):134–138.
44. Xue JC, Schwarz EJ, Chawla A, Lazar MA. Distinct stages in adipogenesis revealed by retinoid inhibition of differentiation after induction of PPARγ. Mol Cell Biol 1996; 16:1567–1575.
45. Schwarz EJ, Reginato MJ, Shao D, Krakow SL, Lazar MA. Retinoic acid blocks adipogenesis by inhibiting C/EBPβ-mediated transcription. Mol Cell Biol 1997; 17(3):1552–1561.
46. DiRenzo J, Soderstrom M, Kurokawa R, Ogliastro MH, Ricote M, Ingrey S, Horlein A, Rosenfeld MG, Glass CK. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators and corepressors. Mol Cell Biol 1997; 17:2166–2176.
47. Brodie AE, Manning VA, Hu CY. Inhibitors of preadipocyte differentiation induce COUP-TF binding to PPAR/RXR binding sequences. Biochem Biophys Res Commun 1996; 228:655–661.
48. Zhang B, Berger J, Hu E, Szalkowski D, White-Carrington S, Spiegelman BM, Möller DE. Negative regulation of peroxisome proliferator-activated recep tor-g gene expression contributes to the adipogenic effect of tumor necrosis factor-α. Mol Endocrinol 1996; 10:1457–1466.
49. Williams PM, Chang DJ, Danesch U, Ringold GM, Heller RA. CCAAT/enhancer binding protein expression is rapidly extinguished in TA1 adipocyte cells treated with tumor necrosis factor. Mol Endocrinol 1992; 6:1135–1141.
50. Ron D, Brasier AR, McGehee REJ, Habener JF. Tumor necrosis factor-Induced reversal of adipocytic phenotype of 3T3-L1 cells is preceded by a loss of nuclear CCAAT/enhancer binding protein (C/EBP). J Clin Invest 1992; 89:223–233.
51. Ntambi JM, Takova T. Role of Ca2+ in the early stages of murine adipocyte differentiation. Differentiation 1996; 60:151–158.
52. Smas CM, Sul HS. Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation. Cell 1993; 73:725–734.
53. Smas CM, Chen L, Sul HS. Cleavage of membrane-associated pref-1 generates a soluble inhibitor of adipocyte differentiation. Mol Cell Biol 1997; 17:977–988.
54. Sul HS, Smas C, Mei B, Zhou L. Function of pref-1 as an inhibitor of adipocyte differentiation. Int J Obes Relat Metab Disord 2000; 24(suppl 4):S15-S19.
55. Smas CM, Chen L, Zhao L, Latasa MJ, Sul HS. Transcriptional repression of pref-1 by glucocorticoids promotes 3T3-L1 adipocyte differentiation. J Biol Chem 1999; 274(18):12632–12641.
56. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, MacDougald OA. Inhibition of adipogenesis by Wnt signaling. Science 2000; 289(5481):950–953.
57. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997; 11: 3286–3305.
58. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis. Genes Dev 2000; 14(11):1293–1307.
59. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994; 79:1147–1156.
60. Hu E, Tontonoz P, Spiegelman BM. Transdifferentiation of myoblasts by the adipogenic transcription factors PPARα and C/EBPa. Proc Natl Acad Sci USA 1995; 92:9856–9860.
61. Yeh WC, Cao Z, Classon M, McKnight S. Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins. Genes Dev 1995; 9:168–181.
62. Wu Z, Xie Y, Bucher NLR, Farmer SR. Conditional ectopic expression of C/EBPβ in NIH-3T3 cells induces PPARγ and stimulates adipogenesis. Genes Dev 1995; 9:2350–2363.
63. Wu Z, Bucher NLR, Farmer SR. Induction of peroxisome proliferator-activated receptor γ during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ, C/EBP6, and glucocorticoids. Mol Cell Biol 1996; 16:4128–4136.
64. Saladin R, Fajas L, Dana S, Halvorsen YD, Auwerx J, Briggs M. Differential regulation of peroxisome proliferator activated receptor γ1 (PPARγ 1) and PPARγ2 mRNA expession in early stages of adipo-genesis. Cell Growth Differ 1999; 10:43–48.
65. Tanaka T, Yoshida N, Kishimoto T, Akira S. Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. EMBO J 1997; 16(24):7432–7443.
66. Hamm JK, Park BH, Farmer SR. A role for C/EBP{beta} in regulating PPAR {gamma} activity during adipogenesis in 3T3-L1 preadipocytes. J Biol Chem 2001; 27:27.
67. Imai T, Jiang M, Chambon P, Metzger D. Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor alpha mediated by a tamoxifen-inducible chimeric Cre recombinase (Cre-ERT2) in adipocytes. Proc Natl Acad Sci USA 2001; 98(1):224–228.
68. Tontonoz P, Kim JB, Graves RA, Spiegelman BM. ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol Cell Biol 1993; 13:4753–4759.
69. Kim JB, Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev 1996; 10:1096–1107.
70. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89:331–340.
71. Bennet MK, Lopez JM, Sanchez HB, Osborne TF. Sterol regulation of fatty acid synthase promoter; coordinate feedback regulation of two major lipid pathways. J Biol Chem 1995; 270:25578–25583.
72. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 1996; 98:1575–1584.
73. Lopez JM, Bennett MK, Sanchez HB, Rosenfeld JM, Osborne TF. Sterol regulation of acetyl coenzyme A carboxylase: a mechanism for coordinate control of cellular lipid. Proc Natl Acad Sci USA 1996; 93:1049–1053.
74. Ericsson J, Jackson SM, Kim JB, Spiegelman BM, Edwards PA. Identification of glycerol-3-phosphate acyltransferase as an adipocyte determination and differentiation factor 1-and sterol regulatory element-binding protein-responsive gene. J Biol Chem 1997; 272:7298–7305.
75. Schoonjans K, Gelman L, Haby C, Briggs M, Auwerx J. Induction of LPL gene expression by sterols is mediated by a sterol regulatory element and is independent of the presence of multiple E boxes. J Mol Biol 2000; 304(3):323–334.
76. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in liver of inorganic mice and in cultured cells. J Clin Invest 1997; 99:846–854.
77. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, J.L. G, Brown MS. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: a model for congenital generalized lipodystrophy. Genes Dev 1998; 12:3182–3194.
78. Wu Z, Rosen ED, Brun R, Hauser S, G. A, Troy AE, McKeon C, Darlington GJ, Spiegelman BM. Crossregulation of C/EBPα and PPARγ controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell 1999; 3:143–150.
79. Wang ND, Finegold MJ, Bradley A, Ou C, Abdel-sayed SV, Wilde MD, Taylor LR, Wilson DR, Darlington GJ. Impaired energy homeostasis in C/EBPα knockout mice. Science 1995; 269(5227):1108–1112.
80. Flodby P, Barlow C, Kylefjord H, Ahrlund-Richter L, Xanthopoulus KG. Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein alpha. J Biol Chem 1996; 271(40):24753–24760.
81. Horvath CM, Darnell JE. The state of the STATs: recent developments in the study of signal transduction to the nucleus. Curr Opin Cell Biol 1997; 9(2):233–239.
82. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001; 13(2):211–217.
83. Stephens JM, Morrison RF, Pilch PF. The expression and regulation of STATs during 3T3-L1 adipocyte differentiation. J Biol Chem 1996; 271: 10441–10444.
84. McAveney KM, Gimble JM, Lee LY. Prolactin receptor expression during adipocyte differentiation of bone marrow stroma. Endocrinology 1996; 137:5723–5726.
85. Zou L, Menon RK, Sperling MA. Induction of mRNAs for the growth hormone receptor gene during 3T3-L1 preadipocyte differentiation. Metabolism 1997;46:114–118.
86. Pradines-Figueres A, Barcellini-Couget S, Dani C, Vannier C, Ailhaud G. Transcriptional control of the expression of lipoprotein lipase gene by growth hormone in preadipocyte Ob1771 cells. J Lipid Res 1990; 31:1283–1291.
87. Francis SM, Enerbäck S, Möller C, Enberg B, Norstedt G. A novel in vitro model for studying signal transduction and gene regulation via growth hormone receptor. Mol Endocrinol 1993; 7:972–978.
88. Nanbu-Wakao R, Fujitani Y, Masuho Y, Muramatu M, Wakao H. Prolactin enhances CCAAT enhancer-binding protein-beta (C/EBP beta) and peroxisome proliferator-activated receptor gamma (PPAR gamma) messenger RNA expression and stimulates adipo-genic conversion of NIH-3T3 cells. Mol Endocrinol 2000; 14(2):307–316.
89. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G, Ihle JN. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998; 93(5):841–850.
90. Deng J, Hua K, Lesser SS, Harp JB. Activation of signal transducer and activator of transcription-3 during proliferative phases of 3T3-L1 adipogenesis. Endocrinology 2000; 141(7):2370–2376.
91. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T, Akira S. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 1997; 94(8):3801–3804.
92. Négrel R, Gaillard D, Ailhaud G. Prostacyclin as a potent effector of adipose-cell differentiation. Biochem J 1989; 257:399–405.
93. Berger J, Tanen M, Elbrecht A, Hermanowski-Vosatka A, Möller DE, Wright SD, Thieringer R. PPAR(gamma) ligands inhibit adipocyte 11 {beta}-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 2001; 22:22.
94. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. Journal of Clinical Investigation 1998; 101:1354–1361.
95. Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, Dugail I, Morin J, Auwerx J, Ferre P. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 1997; 46:1393–1399.
96. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994; 8:1224–1234.
97. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM. PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 1995; 15:351–357.
98. Schoonjans K, Watanabe M, Suzuki H, Mahfoudi A, Krey G, Wahli W, Grimaldi P, Staels B, Yamamoto T, Auwerx J. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem 1995; 270:19269–19276.
99. Martin G, Schoonjans K, Lefebvre A, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein (FATP) and acyl CoA synthetase genes by PPARα and PPARγ activators. J Biol Chem 1997; 272:28210–28217.
100. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman R, Briggs M, Deeb S, Staels B, Auwerx J. PPARα and PPARγ activators direct a tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15:5336–5348.
101. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997; 8:159–166.
102. Auwerx J, Staels B. Leptin. Lancet 1998; 351:737–742.
103. De Vos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong K, Saladin R, Hamann L, Staels B, Briggs MR, Auwerx J. Thiazolidinediones repress ob gene expression via activation of PPARγ. J Clin Invest 1996; 98:1004–1009.
104. Zhang B, Graziano MP, Doebber TW, Leibowitz MD, White-Carrington S, Szalkowski DM, Hey PT, Wu M, Cullinan CA, Bailey P, Lollmann B, Frederich R, Flier JS, Strader CD, Smith RG. Down-regulation of the expression of the obese gene by antidiabetic thiazoli-dinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 1996; 271:9455–9459.
105. Kallen CB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 1996; 93:5793–5796.
106. Miller SG, De Vos P, Guerre-Millo M, Wong K, Hermann T, Staels B, Briggs MR, Auwerx J. The adipocyte specific transcription factor, C/EBPa modulates human ob gene expression. Proc Natl Acad Sci USA 1996; 93:5507–5511.
107. He Y, Chen H, Quon MJ, Reitman M. The mouse obese gene. Genomic organization, promoter activity, and activation by CCAAT/enhancer-binding protein alpha. J Biol Chem 1995; 270:28887–28891.
108. Hollenberg AN, Susulic VS, Madura JP, Zhang B, Möller DE, Tontonoz P, Sarraf P, Spiegelman BM, Lowell BB. Functional antagonism between CCAAT/enhancer binding protein-a and peroxisome prolifer-ator-activated receptor-g on the leptin promoter. J Biol Chem 1997; 272:5283–5290.
109. Torti FM, Dieckman B, Beutler B, Cerami A, Ringold GM. A macrophage factor inhibits adipocyte gene expression; an in vitro model for cachexia. Science 1985; 229:867–869.
110. Beutler B, Cerami A. Cachectin (tumor necrosis factor): a macrophage hormone governing cellular metabolism and inflammatory response. Endocr Rev 1988; 9:57–66.
111. Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signalling. J Clin Invest 1997; 100:1863–1869.
112. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose tissue expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993; 259:87–91.
113. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α-and obesity-induced insulin resistance. Science 1996; 271:665–668.
114. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor a inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994; 91:4854–4858.
115. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS, Spiegelman BM. Altered gene expression for tumor necrosis factor-α and its receptor during drug and dietary modulation of insulin resistance. Endocrinology 1994; 134:264–270.
116. Souza SC, Yamamoto MT, Franciosa MD, Lien P, Greenberg AS. BRL 49653 blocks lipolytic actions of tumor necrosis factor-αlpha: a potential new insulin-sensitizing mechanism for thiazolidinediones. Diabetes 1998; 47:691–695.
117. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001; 409(6818):307–312.
118. Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, Enders GH, Silberg DG, Wen X, Wu GD, Lazar MA. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001; 98(2):502–506.
119. Schoonjans K, Auwerx J. Thiazolidinediones: an update [In Process Citation]. Lancet 2000; 355(9208): 1008–1010.
120. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-D12, 14 prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995; 83:803–812.
121. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehman JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995; 83:813–819.
122. Krey G, Braissant O, L'Horset F, Kalkhoven E, Peroud M, Parker MG, Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by co-activator-dependent receptor ligand assay. Mol Endocrinol 1997; 11:779–791.
123. Ma H, Sprecher HW, Kolattukudy PE. Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in PPARγ-express-ing tissue. J Biol Chem 1998; 273:30131–30138.
124. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA 1997; 94:4318–4323.
125. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA 1997; 94:4312–4317.
126. Nagy L, Tontonez P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 1998; 93: 229–240.
127. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM. The structure activity relationship between peroxisome proliferator activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996; 39:665–668.
128. Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington WW, Jr., Hashim MA, Hull-Ryde EA, Kaldor I, Kliewer SA, Lake DH, Leesnitzer LM, Lehmann JM, Lenhard JM. N-(2-benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 1998; 41(25):5020–5036.
129. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272:3406–3410.
130. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996; 137:4189–4195.
131. Mukherjee R, Davies PAJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Paterniti JR, Heyman RA. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386:407–410.
132. Davies PJ, Berry SA, Shipley GL, Eckel RH, Hennuyer N, Crombie DL, Ogilvie KM, Peinado-Onsurbe J, Fievet C, Leibowitz MD, Heyman RA, Auwerx J. Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity. Mol Pharmacol 2001; 59(2):170–176.
133. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001; 7(l):48–52.
134. Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D, Milstone DS, Mortensen RM, Spiegelman BM, Freeman MW. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 2001; 7(1):41–47.
135. Murakami K, Tobe K, Ide T, Mochizuki T, Ohashi M, Akanuma Y, Yazaki Y, Kadowaki K. A novel insulin sensitizer acts as a coligand for peroxisome prolifer-ator-activated receptor α and γ. Effect of PPARα activation on normal lipid metabolism in liver of Zucker fatty rats. Diabetes 1998; 47:1841–1847.
136. Shibata T, Matsui K, Nagao K, Shinkai H, Yonemori F, Wakitani K. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an iso-xazolidininedione derivative. Eur J Pharmacol 1999; 364:211–219.
137. Lefebvre A-M, Peinado-Onsurbe J, Leitersdorf I, Briggs MR, Paterniti JR, Fruchart J-C, Fievet C, Auwerx J, Staels B. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct, but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol 1997; 17:1756–1764.
138. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, Tanen M, Ventre J, Wu MS, Berger GD, Mosley R. Novel peroxisome proliferator activated receptor (PPAR) γ and PPARγ ligands produce distinct biological effects. J Biol Chem 1999; 274: 6718–6725.
139. Rocchi S, Picarol F, Vamecq J, Gelman L, Potier N, Zeyer D, Dubuquoy L, Bac P, Champy M-F, Plunket KD, Leesnitzer LA, Blanchard SG, Desreumaux P, Moras D, Renaud J-P, Auwerx J. A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 2001; 8:737–747.
140. Möller DE, Flier JS. Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med 1991; 325:938–948.
141. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, Feigenbaum L, Lee E, Aoyama T, Eckhaus M, Reitman ML, Vinson C. Life without fat: a transgenic mouse. Genes Dev 1998; 12:3168–3181.
142. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2:800–803.
143. Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996; 274:1185–1188.
144. Muller G, Ertl J, Gerl M, Preibisch G. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem 1997; 272:10585–10593.
145. Liu YL, Emilson V, Cawthorne MA. Leptin inhibits glycogen synthesis in isolated soleus muscle of obese (ob/ob) mice. FEBS Lett 1997; 411:351–355.
146. Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 1997; 389:374–377.
147. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401(6748):73–76.
148. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98(4):2005–2010.
149. Rosen B, Cook KS, Yaglom J, Groves DL, Volonakis JE, Damm D, White T, Spiegelman BM. Adipsin and complement factor D activity: an immune-related defect in obesity. Science 1989; 244:1483–1487.
150. Frederich RC, Kahn BB, Peach MJ, Flier JS. Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992; 19:339–344.
151. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose-fatty acid cycle: its role in insulin sensitivity and metabolic disturbances of diabetes mellitus. Lancet 1961; i:785–789.
152. Martin G, Schoonjans K, Staels B, Auwerx J. PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 1998; 137:75–80.
153. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, Vanzulli A, Testolin G, Pozza G, Del Maschio A, Luzi L. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999; 48(8):1600–1606.
154. Kim JK, Gavrilova O, Chen Y, Reitman ML, Shulman GI. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 2000; 275(12):8456–8460.
155. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, Reitman ML. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000; 105(3):271–278.
156. Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 2000; 11(9):351–356.
157. Oakes ND, Camilleri S, Furler SM, Chisholm DJ, Kraegen EW. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue availability in the rat. Metabolism 1997; 46:935–942.
158. Wu Z, Xie Y, Morrison RF, Bucher NLR, Farmer SR. PPARγ induces the insulin-dependent glucose transporter GLUT4 in absence of C/EBPα during the conversion of 3T3 fibroblast into adipocytes. J Clin Invest 1998; 101:22–32.
159. Smith U, Gogg S, Johansson A, Olausson T, Rotter V, Svalstedt B. Thiazolidinediones (PPARgamma agonists) but not PPAR alpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB J 2001; 15(1):215–220.
160. Ribon V, Johnson JH, Camp HS, Saltiel AR. Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptor γ activation stimulates expression of the CAP gene. Proc Natl Acad Sci USA 1998; 95:14751–14756.
161. Baumann CA, Ribon V, Kanzaki M, Thurmond DC, Mora S, Shigematsu S, Bickel PE, Pessin JE, Saltiel AR. CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature 2000; 407(6801):202–207.
162. Rieusset J, Auwerx J, Vidal H. Regulation of gene expression by activation of the peroxisome prolifer-ator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun 1999; 265(1):265–271.
163. Burant CF, Sreenan S, Hirano K-I, Tai T-AC, Lohmiller J, Lukens J, Davidson NO, Ross S, Graves RA. Troglitazone action is independent of adipose tissue. J Clin Invest 1997; 100:2900–2908.
164. Kim JB, Sarraf P, Wright M, Yao KM, Mueller E, Solanes G, Lowell BB, Spiegelman BM. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest 1998; 101:1–9.
165. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Goldstein J. Insulin selectively increases SREBP-1c mRNA in the livers of rats with strepto-zotocin-induced diabetes. Proc Natl Acad Sci USA 1999; 96:13656–13661.
166. Foretz M, Guichard C, Ferre P, Foufelle F. Sterol regulatory element binding protein 1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci USA 1999; 96:12737–12742.
167. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice [In Process Citation]. Mol Cell 2000; 6(1):77–86.
168. Fajas L, Schoonjans K, Gelman L, Kim JB, Najib J, Martin G, Fruchart JC, Briggs M, Spiegelman BM, Auwerx J. Regulation of PPARγ expression by ADD-1/SREBP-1: implications for adipocyte differentiation and metabolism. Mol Cell Biol 1999; 19:5495–5503.
169. Kim JB, Wright HM, Wright M, Spiegelman BM. ADD1/SREBP1 activates PPARγ through the production of endogeneous ligand. Proc Natl Acad Sci USA 1998; 95:4333–4337.
170. Croniger C, Trus M, Lysek-Stupp K, Cohen H, Liu Y, Darlington GJ, Poli V, Hanson RW, Reshef L. Role of the isoforms of CCAAT/enhancer-binding protein in the initiation of phosphoenolpyruvate carboxykinase (GTP) gene transcription at birth. J Biol Chem 1997; 272(42):26306–26312.
171. Lee YH, Sauer B, Johnson PF, Gonzalez FJ. Disruption of the C/EBP alpha gene in adult mouse liver. Mol Cell Biol 1997; 17(10):6014–6022.
172. Liu S, Croniger C, Arizmendi C, Harada-Shiba M, Ren J, Poli V, Hanson RW, Friedman JE. Hypoglycemia and impaired hepatic glucose production in mice with a deletion of the C/EBPbeta gene. J Clin Invest 1999; 103(2):207–213.
173. Bouchard C, Perusse L. Genetics of obesity. Annu Rev Nutrition 1993; 13:337–354.
174. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998; 339:953–959.
175. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP-kinase mediated phosphorylation of PPARγ. Science 1996; 274: 2100–2103.
176. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 1997; 272:5128–5132.
177. Camp HS, Tafuri SR. Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J Biol Chem 1997; 272:10811–10816.
178. Zhang B, Berger J, Zhou G, Elbrecht A, Biswas S, White-Carrington S, Szalkowski D, Möller DE. Insulin and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome prolif-erator-activated receptor gamma. J Biol Chem 1996; 271:31771–31774.
179. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR. Molecular scanning of the human peroxisome pro-liferator activated receptor gamma gene in diabetic Caucasians: identification of a Pro12Ala PPARgamma 2 missense mutation. Biochem Biophys Res Commun 1997; 241:270–274.
180. Deeb S, Fajas L, Nemoto M, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in the human peroxisome proliferator-activated receptor gamma2 is associated with decreased receptor activity, improved insulin sensitivity, and lowered body mass index. Nat Genet 1998; 20:284–287.
181. Vigouroux C, Fajas L, Khallouf E, Meier M, Gyapay G, Auwerx J, Weissenbach J, Capeau J, Magre J. Human peroxisome proliferator-activated receptor gamma 2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes 1998; 47:490–492.
182. Beamer BA, Yen CJ, Andersen RE, Muller D, Elahi D, Cheskin LJ, Andres R, Roth J, Shuldiner AR. Association of the Pro12Ala variant in peroxisome proliferator-activated receptor gamma2 gene with obesity in two Caucasian populations. Diabetes 1998; 47:1806–1808.
183. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes [In Process Citation]. Nat Genet 2000; 26(1):76–80.
184. Mori Y, Kim-Motoyama H, Katakura T, Yasuda K, Kadowaki H, Beamer BB, Shuldiner AR, Akanuma Y, Yazaki Y, Kadowaki T. Effect of the Pro12Ala variant of the human peroxisome proliferator activated receptor γ2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem Biophys Res Commun 1998; 251:195–198.
185. Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig A, Flier JS. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1997; 272:20230–20235.
186. Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ, Lazar MA. Interdomain communication regulating ligand binding by PPAR gamma. Nature 1998; 396(6505):377–380.
187. Norman RA, Thompson DB, Foroud T, Garvey WT, Bennett PH, Bogardus C, Ravussin E. Genomewide search for genes influencing percent body fat in Pima Indians: suggestive linkage at chromosome 11Q21 Q22. Am J Hum Genet 1997; 60:166–173.
188. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM. PPARgamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4:585–595.
189. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999; 4:597–609.
190. Miles PD, Barak Y, He W, Evans RM, Olefsky JM. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 2000; 105(3): 287–292.
191. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator-activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996; 1302: 93–109.
192. Staels B, Vu-Dac N, Kosykh V, Saladin R, Fruchart JC, Dallongeville J, Auwerx J. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal Acyl Co-enzyme A Oxidase. J Clin Invest 1995; 95:705–712.
193. Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs, suppression of apolipoprotein C-III. J Biol Chem 1995; 270:13470–13475.
194. Castle CK, Colca JR, Melchior GW. Lipoprotein profile characterization of the KKAy mouse, a rodent model of type II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone. Arte-rioscler Thromb 1993; 13:302–309.
195. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes. N Engl J Med 1998; 338:861–866.
196. Kumar S, Boulton AJM, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 1996; 39:701–709.
197. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997; 46:433–439.
198. Berthezene F. Non-insulin dependent diabetes and reverse cholesterol transport. Atherosclerosis 1996; 124:S39-S42.
199. Sasahara T, Yamashita T, Sviridov D, Fidge N, Nestel P. Altered properties of high density lipoprotein subfractions in obese subjects. J Lipid Res 1997; 38:600–611.
200. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease. Am J Clin Nutr 1956; 34:416–422.
201. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21:697–738.
202. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL recepto-deficient mice. J Clin Invest 2000; 106(4):523–531.
203. Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, Repa JJ, Torpier G, Lobaccaro JM, Paterniti JR, Mangelsdorf DJ, Heyman RA, Auwerx J. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci USA 2001; 98(5):2610–2615.
204. Glass CK, Rose DW, Rosenfeld MG. Nuclear receptor coactivators. Curr Opin Cell Biol 1997; 9:222-232. 203.
205. Abraham SE, Lobo S, Yaciuk P, Heidi HG, Moran E. p300 and p300-associated proteins, are components of the TATA-binding protein (TBP) complexes. Oncogene 1993; 8:1639–1647.
206. Nakajima T, Uchida C, Anderson S, Lee CG, Hurwitz J, Parvin JD, Montmimy M. RNA helicase A mediates association of CBP with RNA polymerase II. Cell 1997; 90:1107–1112.
207. Kingston RE, Narlikar GJ. ATP-dependent remodeling and acetylation as regulators of chromatin fluidity. Genes Dev 1999; 13(18):2339–2352.
208. Vignali M, Hassan AH, Neely KE, Workman JL. ATP-dependent chromatin-remodeling complexes. Mol Cell Biol 2000; 20(6):1899–1910.
209. Sudarsanam P, Winston F. The Swi/Snf family nucleosome-remodeling complexes and transcriptional control [In Process Citation]. Trends Genet 2000; 16(8):345–351.
210. Muchardt C, Yaniv M. A human homologue of Saccharomyces cerevisiae SNF2/SW12 and Drosophila brm genes potentiates transcriptional activation by the glucocorticoid receptor. EMBO J 1993; 12(11):4279–4290.
211. Fryer CJ, Archer TK. Chromatin remodelling by the glucocorticoid receptor requires the BRGI complex. Nature 1998; 393(6680):88–91.
212. Wallberg AE, Neely KE, Hassan AH, Gustafsson JA, Workman JL, Wright AP. Recruitment of the SWI-SNF chromatin remodeling complex as a mechanism of gene activation by the glucocorticoid receptor taul activation domain. Mol Cell Biol 2000; 20(6):2004–2013.
213. Di Lorenzo D, Williams P, Ringold G. Identification of two distinct nuclear factors with DNA binding activity within the glucocorticoid regulatory region of the rat alpha-1-acid glycoprotein promoter. Biochem Biophys Res Commun 1991; 176:1326–1332.
214. Chiba H, Muramatsu M, Nomoto A, Kato H. Two human homologues of Saccharomyces cerevisiae SWI2/SNF2 and Drosophila brahma are transcriptional coactivators cooperating with the oestrogen receptor and the retinoic acid receptor. Nucl Acids Res 1994; 22(10):1815–1820.
215. Dilworth FJ, Fromental-Ramain C, Yamamoto K, Chambon P. ATP-Driven chromatin remodeling activity and histone acetyltransferases act sequentially during transactivation by RAR/RXR In vitro. Mol Cell 2000; 6(5):1049–1058.
216. Lovell-Badge R. Living with bad architecture. Nature 1995; 376:725–726.
217. Zhou X, Benson KF, Ashar HR, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995; 376(6543):771–774.
218. Schoenmakers EFPM, Wanschura S, Mols R, Buller-diek J, Van den Berghe H, Van de Ven WJW. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet 1995; 10:436-443. 217.
219. Ashar HR, Schoenberg Fejzo M, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, Morton CC, Chada K. Disruption of the architectural factor HMGI-C: DNA binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 1995; 82(1):57–65.
220. Battista S, Fidanza V, Fedele M, Klein-Szanto AJ, Outwater E, Brunner H, Santoro M, Croce CM, Fusco A. The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res 1999; 59(19):4793–4797.
221. Melillo RM, Pierantoni GM, Scala S, Battista S, Fedele M, Stella A, De Biasio MC, Chiappetta G, Fidanza V, Condorelli G, Santoro M, Croce CM, Viglietto G, Fusco A. Critical role of the hmgi(y) proteins in adipocytic cell growth and differentiation. Mol Cell Biol 2001; 21(7):2485–2495.
222. Bannister AJ, Kouzarides T. The CBP co-activator is a histone acyltransferase. Nature 1996; 384:641–643.
223. Chen H, Lin RJ, Louis Schiltz L, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms multimeric activation complexes with P/CAF and CBP/p300. Cell 1997; 90:569–580.
224. Korzus E, Torchia J, Rose DW, Xu L, Kurokawa R, McInerney EM, Mullen TM, Glass CK, Rosenfeld MG. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 1998; 279:703–707.
225. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996; 87:953–959.
226. Spencer TEJ, G., Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, O'Malley BW. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 1997; 389:194–198.
227. Martinez-Balbas MA, Bannister AJ, Martin K, Haus-Seuffert P, Meisterernst M, Kouzarides T. The acetyl-transferase activity of CBP stimulates transcription. EMBO J 1998; 17:2886–2893.
228. Imhof A, Yang XJ, Ogryzko VV, Nakatani Y, Wolffe AP, Ge H. Acetylation of general transcription factors by histone acetyltransferases. Curr Biol 1997; 7:689–692.
229. Nagy L, Kao HK, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL, Evans RM. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997; 89:373–380.
230. Alland L, Muhle R, Hou H, Potes J, Chin L, Schreiber-Agus N, DePinho RA. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 1997; 387:49–55.
231. Heinzel T, Lavinsky RM, Mullen TM, Soderstrom M, Laherty CD, Torchia J, Yang W-M, Brard G, Davie JR, Seto E, Eisenman RN, Rose DW, Glass CK, Rosenfeld MG. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 1997; 387:43–48.
232. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000; 14(2):121–141.
233. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995; 377:454–457.
234. Chen DJ, Umesono K, Evans RM. SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers. Proc Natl Acad Sci USA 1996; 93:7567–7571.
235. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld M, Rose DW. Diverse signalling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 1998; 95:2920–2925.
236. Zamir I, Zhang J, Lazar M. Stochiometric and steric principles governing repression by nuclear hormone receptors. Genes Dev 1997; 11:835–846.
237. Misiti S, Schomburg L, Yen PM, Chin WW. Expression and hormonal regulation of co-activator and corepressor genes. Endocrinology 1998; 139:2493–2500.
238. Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993; 365:855–859.
239. Eckner R, Ewen ME, Newsome D, Gerdes M, DeCaprio JA, Bentley Lawrence J, Livingston DM. Molecular cloning and functional analysis of the adenovirus E1A-associated 300 kD protein (p300) reveals a protein with properties of a transcriptional adaptator. Genes Dev 1994; 8:869–884.
240. Janknecht R, Hunter T. Transcriptional control: versatile molecular glue. Curr Biol 1996; 6:951–954.
241. Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, Montminy M, Evans RM. Role of CBP/p300 in nuclear receptor signalling. Nature 1996; 383:99–103.
242. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin S-C, Heyman RA, Rose DW, Glass CK, Rosenfeld MG. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996; 85:403–414.
243. Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, Kurokawa R, Brown M. p300 is a component of an estrogen receptor coactivator complex. Proc Natl Acad Sci USA 1996; 93:11540–11545.
244. Smith CL, Onate SA, Tsai MJ, O'Malley BW. CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc Natl Acad Sci USA 1996; 93:8884–8888.
245. Kraus WL, Kadonaga JT. p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. Genes Dev 1998; 12:331–342.
246. Dowell P, Ishmael JE, Avram D, Peterson VJ, Nevrivy DJ, Leid M. p300 functions as a co-activator for the peroxisome proliferator-activated receptor α. J Biol Chem 1997; 272:33435–33433.
247. Gelman L, Zhou G, Fajas L, Raspe E, Fruchart JC, Auwerx J. p300 interacts with the N-and C-terminal part of PPARγ2 in a ligand-independent and -dependent manner respectively. J Biol Chem 1999; 274:7681–7688.
248. Yao TP, Ku G, Zhou N, Scully R, Livingston DM. The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc Natl Acad Sci USA 1996; 93(20):10626–10631.
249. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995; 270:1354–1357.
250. Zhu Y, Qi C, Calandra C, Rao MS, Reddy J. Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor g. Gene Expr 1996; 6:185–195.
251. Zhou G, Cummings R, Li Y, Mitra S, Wilkinson H, Elbrecht A, Hermes D. Schaeffer J, Smith R, Moller D. Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer. Mol Endocrinol 1998; 12:1594–1604.
252. Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P, Gronemeyer H. The coactivator TIF2 contains three nuclear receptor binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J 1998; 17:507–519.
253. McInermey E, Rose D, Flynn S, Westin S, Krones A, Inostroza J, Torchia J, Nolte R, Assa-Munt N, Milburn M, Glass C, Rosenfeld M. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev 1998; 12:3357–3368.
254. Zhu Y, Qi C, Rao MS, Reddy JK. Isolation of and characterization of PBP, a protein that interacts with peroxisome proliferator activated receptor. J Biol Chem 1997; 272:25500–25506.
255. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998; 92:829-839. 254.
256. Jain S, Pulikuri S, Zhu Y, Qi C, Kanwar YS, Yeldandi AV, Rao MS, Reddy JK. Differential expression of the peroxisome proliferator-activated receptor γ (PPARγ) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am J Pathol 1998; 153:349–354.
257. Fondell JD, Ge H, Roeder RG. Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex. Proc Natl Acad Sci USA 1996; 93(16):8329–8333.
258. Rachez C, Suldan Z, Ward J, Chang CP, Burakov D, Erdjument-Bromage H, Tempst P, Freedman LP. A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes Dev 1998; 12(12):1787–1800.
259. Naar AM, Beaurang PA, Zhou S, Abraham S, Solomon W, Tjian R Composite co-activator ARC mediates chromatin-directed transcriptional activation. Nature 1999; 398(6730):828–832.
260. Gu W, Malik S, Ito M, Yuan CX, Fondell JD, Zhang X, Martinez E, Qin J, Roeder RG. A novel human SRB/MED-containing cofactor complex, SMCC, involved in transcription regulation. Mol Cell 1999; 3(1):97–108.
261. Rachez C, Lemon BD, Suldan Z, Bromleigh V, Gamble M, Naar AM, Erdjument-Bromage H, Tempst P, Freedman LP. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 1999; 398(6730):824–828.
262. Yuan CX, Ito M, Fondell JD, Fu ZY, Roeder RG. The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion [published erratum appears in Proc Natl Acad Sci USA 1998; 95(24):14584]. Proc Natl Acad Sci USA 1998; 95(14):7939–7944.
263. Zhu Y, Qi C, Jia Y, Nye JS, Rao MS, Reddy JK. Deletion of PBP/PPARBP, the gene for nuclear receptor coactivator peroxisome proliferator-acti-vated receptor-binding protein, results in embryonic lethality. J Biol Chem 2000; 275(20):14779–14782.
264. Ito M, Yuan CX, Okano HJ, Darnell RB, Roeder RG. Involvement of the TRAP220 component of the TRAP/SMCC coactivator complex in embryonic development and thyroid hormone action. Mol Cell 2000; 5(4):683–693.
265. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999; 98(1): 115–124.
266. Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 2000; 20(5):1868–1876.
267. Tcherepanova I, Puigserver P, Norris JD, Spiegelman BM, McDonnell DP. Modulation of estrogen recep-tor-alpha transcriptional activity by the coactivator PGC-1. J Biol Chem 2000; 275(21):16302–16308.
268. Knutti D, Kaul A, Kralli A. A tissue-specific coactivator of steroid receptors, identified in a functional genetic screen. Mol Cell Biol 2000; 20(7):2411–2422.
269. Puigserver P, Adelmant G, Wu Z, Fan M, Xu J, O'Malley B, Spiegelman BM. Activation of PPAR-gamma coactivator-1 through transcription factor docking. Science 1999; 286(5443):1368–1371.
270. Michael LF, Wu Z, Cheatham RB, Puigserver P, Adelmant G, Lehman JJ, Kelly DP, Spiegelman BM. Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad Sci USA 2001; 98(7):3820–3825.
271. Monsalve M, Wu Z, Adelmant G, Puigserver P, Fan M, Spiegelman BM. Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1. Mol Cell 2000; 6(2):307–316.
272. Treuter E, Albrektsen T, Johansson L, Leers J, Gustafsson JA. A regulatory role for RIP140 in nuclear receptor activation. Mol Endocrinol 1998; 12(6):864–881.
273. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93:241–252.
274. Lefebvre A, Chen I, Desreumaux P, Najib J, Fruchart J, Geboes K, Briggs M, Heyman R, Auwerx J. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin /+ mice. Nat Med 1998; 4:1053–1057.
275. Saez E, Tontonoz P, Nelson MC, Alvarez JGA, Ming UT, Baird SM, Thomazy VA, Evans RM. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med 1998; 4:1058–1061.
276. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338:916–917.